Tempus acquires Personalis for around $1.5 billion, adding the MRD monitoring layer to its oncology platform 🔗

What happened: On July 20, Tempus agreed to buy cancer genomics company Personalis for $16.25 per share, paid primarily in Tempus stock with the option to cover up to half in cash. That is about a 6% premium to Personalis' July 17 close. Both boards approved the deal, which is expected to close in late 2026 or early 2027, pending Personalis shareholder and regulatory approval. The target is NeXT Personal, a minimal residual disease test that tracks circulating tumour DNA to catch recurrence before it shows on a scan, and which already has Medicare coverage in three indications.

Why it matters: AI oncology is consolidating around monitoring. The deal builds on a partnership that began in 2023, when Tempus took a stake in Personalis and started commercialising the test, and it follows Tempus' 2025 purchase of digital pathology company Paige. Tempus is assembling a diagnosis-to-recurrence continuum, with the companies framing MRD as a $20 billion market.

Bristol Myers Squibb commits to a second NVIDIA supercomputer for drug discovery 🔗

What happened: On July 20, BMS said it will deploy a second NVIDIA DGX SuperPOD, built on eight DGX Vera Rubin NVL72 systems, which it describes as the most powerful and energy-efficient single-owned NVIDIA infrastructure in life sciences. The system delivers up to ten times the performance per megawatt of its predecessor and extends a collaboration that began about three years ago. BMS ties the compute to its "Predict First" approach, using AI to inform experimental design earlier.

Why it matters: BMS is the latest large pharma, after Lilly and Roche, to claim the biggest in-house AI cluster in the sector, and the careful "single-owned" qualifier is doing real work in that claim. The broader signal is that major drugmakers are choosing to own frontier compute rather than rent it, a decision that locks in architecture for years.

Dimension closes an $800 million fund for AI and biology 🔗

What happened: On July 21, the venture firm Dimension announced an $800 million third fund, 60% larger than its $500 million second fund from December 2024, bringing assets under management to $1.65 billion across 35 portfolio companies. Dimension co-led Chai Discovery's seed round and co-founded Coefficient Bio, which Anthropic acquired in April 2026 for about $400 million.

Why it matters: Capital for the intersection of AI and biology keeps scaling, and the same platform names recur across these deals. The firm's own founders have said their thesis is playing out faster than they expected, which is itself a signal about how quickly timelines are compressing.

Cheiron raises an $8 million seed to turn a drug program into software 🔗

What happened: On July 22, Los Altos startup Cheiron announced an $8 million seed led by Menlo Ventures, with backing from Moderna co-founder Robert Langer, former Pfizer CMO Freda Lewis-Hall, Chai Discovery CEO Josh Meier and former Apple AI chief John Giannandrea. Founded in 2024, Cheiron builds an AI-native operating system that represents a whole drug program, its evidence, assumptions, risks and decisions, as one connected system on a proprietary Life Sciences Knowledge Graph. It reports deployment at drug developers including Boryung within six months of launch.

Why it matters: Cheiron is making the same bet as the Dassault and ArisGlobal deal, from the startup side: that the value lies in pulling a fragmented layer of drug development into one connected, auditable system. Dassault is assembling that layer by acquisition, while Cheiron is building it natively, turning the evidence, filings and institutional knowledge scattered across a program into a single working picture.

The White House science blueprint names life sciences as an area to step back from 🔗

What happened: On July 21, OSTP Director Michael Kratsios released "Science: A New Golden Age," a report calling for hundreds of billions in federal research funding to shift from universities toward industry, with priority on AI, robotics and nuclear energy. Testifying to the House Science Committee the next day, Kratsios said the administration would reduce the government's focus on what he termed life sciences. The report is modelled on Vannevar Bush's 1945 "Science, the Endless Frontier," and reactions in Congress split along party lines.

Why it matters: US life sciences runs on a pipeline in which federally funded basic research feeds industry. An explicit federal tilt away from that category, whatever one's read on the politics, is a long-horizon variable worth tracking for anyone building on the assumption that public research funding keeps flowing at current levels.